The cluster is small in dollar terms but involves multiple C-suite executives selling on the same day, which is atypical for routine diversification. Monitor for any upcoming pipeline data readouts or regulatory updates that could explain the timing. The strong historical win rate (60% T+20) on OCUL reports suggests the stock has been trending favorably, but the insider sales introduce a cautionary note.
Price Chart
Executive Summary
Five senior executives at Ocular Therapeutix, including the Chief Scientific Officer, Chief Operating Officer, and Chief Development Officer, sold a total of ~$333K in shares over a one-week period. While the dollar amount is modest relative to the $2.4B market cap (0.01%), the cluster involves multiple C-suite insiders selling on the same day, which warrants attention despite the academic literature showing cluster sales are less informative than buys. The sales follow a strong recent stock performance and occur ahead of potential pipeline catalysts for the company's lead drug candidate.
Key Financial Metrics
Key Facts
- Five insiders sold shares totaling ~$333K from Aug 24-31, 2026
- Sales include CSO, COO, Chief Development Officer, Chief Strategy Officer, and a senior executive
- All sales were open-market transactions at prices between $10.24-$10.78
- Total sales represent ~0.01% of OCUL's $2.4B market cap
- No insider purchases were reported in the cluster window
Financial Impact
~$333K in insider sales, representing 0.01% of market cap
Risk Factors
- Insider sales may signal management caution ahead of pipeline milestones
- Stock has shown high volatility with recent T+20 moves ranging from -14.4% to +24.9%
- No insider buying to offset the selling cluster
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-OCUL-1788412176966 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | Insider Cluster | $10.90 $7.67 | ▼ −29.63% | ▼ −29.30% | $6.96 (−36.15%) |
Aug 26, 2026 5w ago | Insider Cluster | $10.82 $9.82 | ▼ −9.24% | ▼ −8.73% | $6.96 (−35.67%) |
Aug 3, 2026 8w ago | 8-K | $8.40 $10.49 | ▲ +24.88% | ▲ +23.64% | $6.96 (−17.14%) |
Jun 17, 2026 15w ago | Press Release | $9.64 $9.17 | ▼ −4.93% | ▼ −6.24% | $6.96 (−27.80%) |
Jun 12, 2026 16w ago | 8-K | $8.99 $9.88 | ▲ +9.90% | ▲ +10.65% | $6.96 (−22.58%) |
Jun 4, 2026 17w ago | Press Release | $8.80 $9.64 | ▲ +9.55% | ▲ +10.92% | $6.96 (−20.91%) |
May 28, 2026 18w ago | Insider Cluster | $9.01 $9.90 | ▲ +9.88% | ▲ +11.67% | $6.96 (−22.75%) |
May 5, 2026 21w ago | 8-K | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
May 5, 2026 21w ago | Press Release | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
Apr 30, 2026 22w ago | DEFA14A | $9.43 $8.93 | ▼ −5.30% | ▼ −10.57% | $6.96 (−26.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access